Effects of proton pump inhibitors and histamine-2 receptor antagonists on response to fidaxomicin or vancomycin in patients with Clostridium difficile-Associated diarrhea

BMJ Open Gastroenterology

Volumn 2, Issue 1, 2015, Pages

  Weiss, Karl ^a   Louie, Thomas ^b   Miller, Mark A ^c   Mullane, Kathleen ^d   Crook, Derrick W ^e   Gorbach, Sherwood L ^f  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d UNIVERSITY OF CHICAGO   (United States)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIMETIDINE; CREATININE; ESOMEPRAZOLE; FAMOTIDINE; FIDAXOMICIN; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PLACEBO; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE; SERUM ALBUMIN; VANCOMYCIN;

ADOLESCENT; ADULT; ADVERSE EVENT; AGED; ALBUMIN BLOOD LEVEL; ANTIBIOTIC THERAPY; ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HOSPITAL PATIENT; HUMAN; HYPOALBUMINEMIA; INTENTION TO TREAT ANALYSIS; LEUKOCYTOSIS; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; TREATMENT DURATION; TREATMENT RESPONSE; VERY ELDERLY;

EID: 85013375588     PISSN: None     EISSN: 20544774     Source Type: Journal    
DOI: 10.1136/bmjgast-2014-000028     Document Type: Article

References (34)

1. Dial S, Delaney JA, Schneider V, et al. Proton pump inhibitor use and risk of community-Acquired Clostridium difficile-Associated disease defined by prescription for oral vancomycin therapy. CMAJ 2006;175:745-8.
2. Howell MD, Novack V, Grgurich P, et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med 2010;170:784-90.
3. Stevens V, Dumyati G, Brown J, et al. Differential risk of Clostridium difficile infection with proton pump inhibitor use by level of antibiotic exposure. Pharmacoepidemiol Drug Saf 2011;20:1035-42.
4. Aseeri M, Schroeder T, Kramer J, et al. Gastric acid suppression by proton pump inhibitors as a risk factor for Clostridium difficile-Associated diarrhea in hospitalized patients. Am J Gastroenterol 2008;103:2308-13.
5. Seto CT, Jeraldo P, Orenstein R, et al. Prolonged use of a proton pump inhibitor reduces microbial diversity: implications for Clostridium difficile susceptibility. Microbiome 2014;2:42.
6. Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol 2007;102:2047-57.
7. Dial S, Delaney JA, Barkun AN, et al. Use of gastric acid-suppressive agents and the risk of community-Acquired Clostridium difficile-Associated disease. JAMA 2005;294:2989-95.
8. Garey KW, Sethi S, Yadav Y, et al. Meta-Analysis to assess risk factors for recurrent Clostridium difficile infection. J Hosp Infect 2008;70:298-304.
9. Linsky A, Gupta K, Lawler EV, et al. Proton pump inhibitors and risk for recurrent Clostridium difficile infection. Arch Intern Med 2010;170:772-8.
10. Chayanupatkul M, Weber JS, Pomerantz S, et al. The use of proton pump inhibitors is associated with the increased severity of Clostridium difficile-Associated diarrhea and recurrent disease in African American patients: The preliminary report. Gastroenterology 2013;144(Suppl 1):S236.
11. Lupse M, Flonta M, Cioara A, et al. Predictors of first recurrence in Clostridium difficile-Associated disease. A study of 306 patients hospitalized in a Romanian tertiary referral center. J Gastrointestin Liver Dis 2013;22:397-403.
12. Kim YG, Graham DY, Jang BI. Proton pump inhibitor use and recurrent Clostridium difficile-Associated disease: A case-control analysis matched by propensity score. J Clin Gastroenterol 2012;46:397-400.
13. Thomas L, Culley EJ, Gladowski P, et al. Longitudinal analysis of the costs associated with inpatient initiation and subsequent outpatient continuation of proton pump inhibitor therapy for stress ulcer prophylaxis in a large managed care organization. J Manag Care Pharm 2010;16:122-9.
14. Pham CQ, Regal RE, Bostwick TR, et al. Acid suppressive therapy use on an inpatient internal medicine service. Ann Pharmacother 2006;40:1261-6.
15. Vakil N. Prescribing proton pump inhibitors: is it time to pause and rethink? Drugs 2012;72:437-45.
16. Batuwitage BT, Kingham JG, Morgan NE, et al. Inappropriate prescribing of proton pump inhibitors in primary care. Postgrad Med J 2007;83:66-8.
17. Heidelbaugh JJ, Goldberg KL, Inadomi JM. Magnitude and economic effect of overuse of antisecretory therapy in the ambulatory care setting. Am J Manag Care 2010;16: 228-34.
18. Ramirez E, Lei SH, Borobia AM, et al. Overuse of PPIs in patients at admission, during treatment, and at discharge in a tertiary Spanish hospital. Curr Clin Pharmacol 2010;5:288-97.
19. Reid M, Keniston A, Heller JC, et al. Inappropriate prescribing of proton pump inhibitors in hospitalized patients. J Hosp Med 2012;7:421-5.
20. Grant K, Al-Adhami N, Tordoff J, et al. Continuation of proton pump inhibitors from hospital to community. Pharm World Sci 2006;28:189-93.
21. Rashid S, Rajan D, Jacob R, et al. Inappropriate use of gastric acid suppression therapy and its relationship to Clostridium difficile-Associated diarrhea in an inpatient setting: A ten-year retrospective analysis. Am J Gastroenterol 2011;106(Suppl 2): S420-S451.
22. FDA Drug Safety Communication: clostridium difficile-Associated diarrhea can be associated with stomach acid drugs known as proton pump inhibitors (PPIs). http://www.fda.gov/drugs/drugsafety/ucm290510.htm (accessed 8 Feb 2012).
23. Venugopal AA, Johnson S. Fidaxomicin: A novel macrocyclic antibiotic approved for treatment of Clostridium difficile infection. Clin Infect Dis 2012;54:568-74.
24. [No authors listed]. Fidaxomicin: difimicin; lipiarmycin; OPT 80; OPT-80; PAR 101; PAR-101. Drugs R D 2010;10: 37-45.
25. Mullane KM, Gorbach S. Fidaxomicin: first-in-class macrocyclic antibiotic. Expert Rev Anti Infect Ther 2011;9:767-77.
26. Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011;364:422-31.
27. Poxton IR. Fidaxomicin: A new macrocyclic, RNA polymerase-inhibiting antibiotic for the treatment of Clostridium difficile infections. Future Microbiol 2010;5:539-48.
28. Cornely OA, Crook DW, Esposito R, et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: A double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis 2012;12:281-9.
29. Bauer MP, Miller M, Gerding DN, et al. Renal failure, fever, and leukocytosis all predict treatment failure in Clostridium difficile infection (CDI), but renal failure is the only predictor of recurrent CDI. Clin Microbiol Infect 2011;17(Suppl 4):A2-A3.
30. Fernandez A, Anand G, Friedenberg F. Factors associated with failure of metronidazole in Clostridium difficile-Associated disease. J Clin Gastroenterol 2004;38:414-18.
31. Hu MY, Maroo S, Kyne L, et al. A prospective study of risk factors and historical trends in metronidazole failure for Clostridium difficile infection. Clin Gastroenterol Hepatol 2008;6:1354-60.
32. Muto CA, Pokrywka M, Shutt K, et al. A large outbreak of Clostridium difficile-Associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 2005;26:273-80.
33. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-Associated diarrhea with high morbidity and mortality. N Engl J Med 2005;353:2442-9.
34. Pépin J, Alary ME, Valiquette L, et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 2005;40:1591-7.